ACHV · Insider Trading
Achieve Life Sciences, Inc.
Every open-market purchase and sale reported by ACHV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Benjamin Halladay | Chief Financial Officer | A | +400,000 deriv. | — |
| 2026-08-21 | Richard Alistair Stewart | Director | Sell | −20,626 | −$175.18K |
| 2026-07-29 | Aaron Royston | Director | A | +41,700 deriv. | — |
| 2026-07-29 | Thomas Sellig | Director | A | +41,700 deriv. | — |
| 2026-07-29 | Nancy R. Phelan | Director | A | +41,700 deriv. | — |
| 2026-07-29 | Jeffrey S Farrow | Director | A | +41,700 deriv. | — |
| 2026-07-29 | Richard Alistair Stewart | Director | A | +41,700 deriv. | — |
| 2026-07-29 | Reid Alexander Waldman | Director | A | +41,700 deriv. | — |
| 2026-07-29 | Christopher Nathan Martin | Director | A | +41,700 deriv. | — |
| 2026-06-02 | Jeffrey S Farrow | Director | A | +47,250 deriv. | — |
| 2026-06-02 | Reid Alexander Waldman | Director | A | +47,250 deriv. | — |
| 2026-05-13 | Christopher Nathan Martin | Director | A | +47,250 deriv. | — |
| 2026-04-21 | Andrew D. Goldberg | CEO and President | A | +17,109,164 deriv. | — |
| 2026-01-30 | Craig Donnelly | Chief Operations Officer | A | +180,000 deriv. | — |
| 2026-01-30 | Mark K Oki | Chief Financial Officer | A | +180,000 deriv. | — |
| 2026-01-30 | Jerry Wan | Principal Accounting Officer | A | +70,300 deriv. | — |
| 2026-01-30 | Richard Alistair Stewart | Chief Executive Officer | A | +645,000 deriv. | — |
| 2026-01-30 | Mark Lawrence Rubinstein | Chief Medical Officer | A | +180,000 deriv. | — |
| 2026-01-30 | Jaime Xinos | Chief Commercial Officer | A | +180,000 deriv. | — |
| 2025-12-08 | Erik Atkisson | Chief Legal Officer | A | +250,000 deriv. | — |
| 2025-10-03 | Craig Donnelly | Chief Operations Officer | A | +50,000 deriv. | — |
| 2025-09-22 | Richard Alistair Stewart | Chief Executive Officer | MIXED | +167,999 | −$378.14K |
| 2025-09-22 | Mark K Oki | Chief Financial Officer | MIXED | +117,940 | −$146.18K |
| 2025-09-08 | Jaime Xinos | Chief Commercial Officer | MIXED | +48,146 | −$57.77K |
| 2025-09-08 | Cindy Jacobs | President & CMO | MIXED | +82,371 | −$76.53K |
| 2025-09-08 | Mark K Oki | Chief Financial Officer | A | −168,000 deriv. | — |
| 2025-09-08 | Jerry Wan | Principal Accounting Officer | MIXED | +20,030 | −$38.97K |
| 2025-09-08 | Thomas Braxton King | Director | MIXED | +315,142 | −$387.41K |
| 2025-09-08 | Richard Alistair Stewart | Chieve Executive Officer | A | −297,500 deriv. | — |
| 2025-06-10 | Nancy R. Phelan | Director | A | +31,500 deriv. | — |
| 2025-06-10 | Stuart Duty | Director | A | +31,500 deriv. | — |
| 2025-06-10 | Thomas Sellig | Director | A | +31,500 deriv. | — |
| 2025-06-10 | Bridget A Martell | Director | A | +31,500 deriv. | — |
| 2025-06-10 | Kristen B. Slaoui | Director | A | +31,500 deriv. | — |
| 2025-06-10 | Thomas Braxton King | Director | A | +31,500 deriv. | — |
| 2025-03-19 | Richard Alistair Stewart | Chieve Executive Officer | Buy | +10,000 | +$28.60K |
| 2025-03-19 | Mark K Oki | Chief Financial Officer | Buy | +10,000 | +$28.89K |
| 2025-01-30 | Cindy Jacobs | President & CMO | A | +130,000 deriv. | — |
| 2025-01-30 | Jaime Xinos | Chief Commercial Officer | A | +100,000 deriv. | — |
| 2025-01-30 | Jerry Wan | Principal Accounting Officer | A | +48,000 deriv. | — |
| 2025-01-14 | Kristen B. Slaoui | Director | A | +47,250 deriv. | — |
| 2025-01-14 | Jaime Xinos | Chief Commercial Officer | A | +20,000 deriv. | — |
| 2025-01-14 | Nancy R. Phelan | Director | A | +47,250 deriv. | — |
| 2025-01-14 | Richard Alistair Stewart | Chieve Executive Officer | A | +225,000 deriv. | — |
| 2025-01-14 | Thomas Braxton King | Executive Chairman | A | +650,000 deriv. | — |
| 2024-12-09 | Jaime Xinos | Chief Commercial Officer | A | +30,000 deriv. | — |
| 2024-12-09 | Mark K Oki | Chief Financial Officer | A | +240,000 deriv. | — |
| 2024-08-20 | Jerry Wan | Principal Accounting Officer | A | +2,857 | +$10.49K |
| 2024-08-20 | John Bencich | CEO | A | +5,000 | +$18.35K |
| 2024-08-20 | Cindy Jacobs | President & CMO | A | +2,660 | +$9.76K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Thomas Braxton King | Executive Chairman | 315,142 | $2.08M |
| Richard Alistair Stewart | Chief Executive Officer | 209,131 | $1.38M |
| Cindy Jacobs | President & CMO | 143,214 | $945.93K |
| Mark K Oki | Chief Financial Officer | 127,940 | $845.04K |
| Jaime Xinos | Chief Commercial Officer | 95,286 | $629.36K |
| Jerry Wan | Principal Accounting Officer | 32,694 | $215.94K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACHV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.